Longitudinal change of circulating tumor cell level and its relationship with immune checkpoint inhibitor-based treatment benefits in unresectable, metastatic colorectal cancer patients

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021; 325(7):669–685.
   PubMed Web of Science ®Google Scholar
• De Falco V, Napolitano S, Rosello S, et al. How we treat metastatic colorectal cancer. ESMO Open. 2020; 4(Suppl 2):e000813.
   PubMedGoogle Scholar
• Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837–3849.
   PubMed Web of Science ®Google Scholar
• Cui G. Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: strategies and perspectives. Biomed Pharmacother. 2022; 149:112923.
   PubMed Web of Science ®Google Scholar
• Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therap Adv Gastroenterol. 2021;14:17562848211024460.
   Web of Science ®Google Scholar
• Casak SJ, Marcus L, Fashoyin-Aje L, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 2021; 27(17):4680–4684.
   PubMed Web of Science ®Google Scholar
• Veyrune L, Naumann DN, Christou N. Circulating tumour cells as prognostic biomarkers in colorectal cancer: a systematic review. Int J Mol Sci. 2021; 22(8):3437.
   PubMed Web of Science ®Google Scholar
• Pan X, Zhang X. Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer. Future Oncol. 2020; Jun16(18):1289–1299.
   PubMed Web of Science ®Google Scholar
• Chu HY, Yang CY, Yeh PH, et al. Highly correlated recurrence prognosis in patients with metastatic colorectal cancer by synergistic consideration of circulating tumor cells/microemboli and tumor markers CEA/CA19-9. Cells. 2021; 10(5):1149.
   PubMed Web of Science ®Google Scholar
• Abdalla TSA, Meiners J, Riethdorf S, et al. Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer. PLOS One. 2021;16(6):e0252897.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou S, Zhang W, et al. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients. Int J Colorectal Dis. 2019; 34(4):589–597.
   PubMed Web of Science ®Google Scholar
• Tsai WS, You JF, Hung HY, et al. Novel circulating tumor cell assay for detection of colorectal adenomas and cancer. Clin Transl Gastroenterol. 2019; 10(10):e00088.
   PubMed Web of Science ®Google Scholar
• Tsai WS, Hung WS, Wang TM, et al. Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer. Biomed J. 2021; 44(6 Suppl 2):S190–S200.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhao L, Zhou P, et al. Circulating tumor microemboli (CTM) and vimentin + circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Cancer Cell Int. 2017;17:6.
   PubMed Web of Science ®Google Scholar
• Gorges TM, Stein A, Quidde J, et al. Improved detection of circulating tumor cells in metastatic colorectal cancer by the combination of the CellSearch(R) system and the AdnaTest(R). PLOS One. 2016;11(5):e0155126.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Chantzara E, Xenidis N, Kallergi G, et al. Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. Expert Rev Mol Diagn. 2021;21(10):1037–1048.
   PubMed Web of Science ®Google Scholar
• Mandair D, Khan MS, Lopes A, et al. Prognostic threshold for circulating tumor cells in patients with pancreatic and midgut neuroendocrine tumors. J Clin Endocrinol Metab. 2021; 106(3):872–882.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gu X, Zuo Z, et al. Prognostic value of circulating tumor cells in patients with bladder cancer: a meta-analysis. PLOS One. 2021;16(7):e0254433.
   PubMed Web of Science ®Google Scholar
• Marcuello M, Vymetalkova V, Neves RPL, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspects Med. 2019; 69:107–122.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yuan Z, Zhu S, et al. The longitudinal change of circulating tumor cell during chemotherapy and its correlation with disease features, treatment response and survival profile of advanced gallbladder carcinoma. Am J Transl Res. 2021;13(12):13590–13598.
   PubMed Web of Science ®Google Scholar
• Castro-Giner F, Aceto N. Tracking cancer progression: from circulating tumor cells to metastasis. Genome Med. 2020; 12(1):31.
   PubMed Web of Science ®Google Scholar
• Yu X, Li S, Xu Y, et al. Androgen maintains intestinal homeostasis by inhibiting BMP signaling via intestinal stromal cells. Stem Cell Rep. 2020; 15(4):912–925.
   PubMed Web of Science ®Google Scholar
• Zhong X, Zhang H, Zhu Y, et al. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer. 2020; 19(1):15.
   PubMed Web of Science ®Google Scholar
• Herath S, Razavi Bazaz S, Monkman J, et al. Circulating tumor cell clusters: insights into tumour dissemination and metastasis. Expert Rev Mol Diagn. 2020;20(11):1139–1147.
   PubMed Web of Science ®Google Scholar
• Li H, Liu Q, Liang S, et al. Circulating tumor cells and neutrophil-lymphocyte ratio are predictive markers for metastatic colorectal cancer patients. Transl Cancer Res. 2021; 10(1):288–297.
   PubMed Web of Science ®Google Scholar